Rankings
▼
Calendar
AXSM FY 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
AXSM
Axsome Therapeutics, Inc.
$9B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$271M
+440.8% YoY
Gross Profit
$245M
90.4% margin
Operating Income
-$232M
-85.7% margin
Net Income
-$239M
-88.4% margin
EPS (Diluted)
$-5.27
Cash Flow
Operating Cash Flow
-$145M
Free Cash Flow
-$146M
Stock-Based Comp.
$63M
Balance Sheet
Total Assets
$588M
Total Liabilities
$397M
Stockholders' Equity
$191M
Cash & Equivalents
$386M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$271M
$50M
+440.8%
Gross Profit
$245M
$45M
+445.4%
Operating Income
-$232M
-$180M
-28.9%
Net Income
-$239M
-$187M
-27.8%
← Q4 2022
All Quarters
Q1 2023 →